NCT02631109

L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Beijing Friendship Hospital · Academic / Other
• Sex: All
• Age: 14 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study aimed to investigate the efficacy and safety of Pegaspargase together with liposomal doxorubicin, etoposide and high dose methylprednisolone (L-DEP) as a salvage therapy for refractory Epstein Barr virus-induced hemophagocytic lymphohistiocytosis.

Conditions

• Hemophagocytic Lymphohistiocytosis

Interventions

Type	Name	Description
DRUG	Pegaspargase	2000U/m2 day5
DRUG	doxorubicin	25mg/m2 day1
DRUG	etoposide	100 mg/m2 was administered once on the first day of every week
DRUG	methylprednisolone	15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7

Timeline

• Start date: 2015-12-01
• Primary completion: 2017-11-01
• Completion: 2019-11-01
• First posted: 2015-12-16
• Last updated: 2016-08-04

Locations

1 site across 1 country: China